Janssen-Cilag International NV, a Johnson & Johnson company (NYSE:JNJ) announced Friday that an expert panel of the EU drug ...
A Johnson & Johnson unit working to resolve massive cancer litigation in bankruptcy court was accused by a former head of the ...
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results